High Flow Nasal Cannula Compared to Standard Oxygen for Endoscopic Ultrasound

January 5, 2026 updated by: Bhargavi Gali, M.D., Mayo Clinic

High Flow Nasal Cannula Compared to Standard Oxygen Therapy for Endoscopic Ultrasound Procedure in High Risk Patients on Recovery Time and Procedural Conditions

The purpose of the study is to evaluate the use of high flow nasal cannula versus standard oxygen therapy for high-risk patients undergoing endoscopy procedures.

Study Overview

Status

Enrolling by invitation

Conditions

Intervention / Treatment

Detailed Description

Patients with a higher BMI are at greater risk for lower oxygen levels which can delay the endoscopy procedure. This research is being conducted to find out if high risk patients will have a shorter recovery time and improved procedural conditions with a high flow nasal cannula versus standard oxygen therapy.

Study Type

Interventional

Enrollment (Estimated)

200

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Minnesota
      • Rochester, Minnesota, United States, 55901
        • Mayo Clinic

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

• All patients age 18 years and older who present to Gonda 2 procedural area for Endoscopic ultrasound (EUS) with or without endoscopy (EGD)/biopsy/tissue sampling. with BMI ≥ 35 kg/m2 (BMI within the past 6 months in electronic medical records or at current procedure) who are able to consent will be approached for potential enrollment.

Exclusion Criteria:

  • Need for general anesthesia for the procedure instead of the standard monitored anesthesia care.
  • Patients undergoing combined procedure: Therapeutic EUS/combined procedures including EUS/ERCP, EUS/colonoscopy
  • Patients on home oxygen therapy, or the diagnosis of "severe COPD"
  • Patients with existing tracheostomy
  • Inpatients undergoing EUS
  • Inability to consent
  • Cognitive impairment
  • Blocked nasal passages
  • Trauma/previous surgery to the nasopharynx
  • Irregularities of the nose, face, or airway such that HFNC cannot be properly fitted

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Standard oxygen therapy
Standard oxygen therapy will be initiated utilizing 2-4 liters of oxygen with a nasal cannula.
Experimental: High Flow Nasal Cannula
A high flow oxygen device with 100% FiO2 will be initiated prior to endoscopic ultrasound.
Other: High flow nasal cannula
Subjects undergoing endoscopic ultrasound will receive high flow nasal cannula during the procedure

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Decrease recovery time
Time Frame: 4 hours
Time measured in minutes for participants to enter post anesthesia care until the nurse marks "ready for discharge" in the medical record.
4 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Improve procedural conditions
Time Frame: 1 hour
Decreased number of times the procedure is paused or delayed.
1 hour

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Mayo Clinic

Collaborators

Fisher and Paykel Healthcare

Investigators

  • Principal Investigator: Bhargavi Gali, MD, MHA, Mayo Clinic

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 14, 2025

Primary Completion (Estimated)

September 1, 2026

Study Completion (Estimated)

October 1, 2026

Study Registration Dates

First Submitted

November 20, 2024

First Submitted That Met QC Criteria

November 25, 2024

First Posted (Actual)

November 26, 2024

Study Record Updates

Last Update Posted (Actual)

January 7, 2026

Last Update Submitted That Met QC Criteria

January 5, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 24-003924

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Endoscopic Ultrasound

Clinical Trials on High flow nasal cannula

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe